These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
206 related articles for article (PubMed ID: 23590816)
1. Therapies for obesity and medication-associated weight gain. Howland RH J Psychosoc Nurs Ment Health Serv; 2013 May; 51(5):13-6. PubMed ID: 23590816 [TBL] [Abstract][Full Text] [Related]
2. Formulary management of 2 new agents: lorcaserin and phentermine/topiramate for weight loss. Kelly EM; Tungol AA; Wesolowicz LA J Manag Care Pharm; 2013 Oct; 19(8):642-54. PubMed ID: 24074010 [TBL] [Abstract][Full Text] [Related]
3. Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis. Khera R; Murad MH; Chandar AK; Dulai PS; Wang Z; Prokop LJ; Loomba R; Camilleri M; Singh S JAMA; 2016 Jun; 315(22):2424-34. PubMed ID: 27299618 [TBL] [Abstract][Full Text] [Related]
4. Lorcaserin, phentermine topiramate combination, and naltrexone bupropion combination for weight loss: the 15-min challenge to sort these agents out. Citrome L Int J Clin Pract; 2014 Dec; 68(12):1401-5. PubMed ID: 25418525 [No Abstract] [Full Text] [Related]
5. New antiobesity agents: lorcaserin (Belviq) and phentermine/topiramate ER (Qsymia). Shyh G; Cheng-Lai A Cardiol Rev; 2014; 22(1):43-50. PubMed ID: 24304809 [TBL] [Abstract][Full Text] [Related]
6. Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease. Bays H Expert Rev Cardiovasc Ther; 2010 Dec; 8(12):1777-801. PubMed ID: 20707765 [TBL] [Abstract][Full Text] [Related]
10. Drug treatment of obesity: current status and future prospects. Kakkar AK; Dahiya N Eur J Intern Med; 2015 Mar; 26(2):89-94. PubMed ID: 25634851 [TBL] [Abstract][Full Text] [Related]
11. Obesity Epidemic: Pharmaceutical Weight Loss. Curry SA R I Med J (2013); 2017 Mar; 100(2):18-20. PubMed ID: 28246654 [TBL] [Abstract][Full Text] [Related]
12. Safety assessment of combination therapies in the treatment of obesity: focus on naltrexone/bupropion extended release and phentermine-topiramate extended release. Halpern B; Mancini MC Expert Opin Drug Saf; 2017 Jan; 16(1):27-39. PubMed ID: 27732121 [TBL] [Abstract][Full Text] [Related]
13. Current and emerging pharmacotherapies for obesity in Australia. Hocking S; Dear A; Cowley MA Obes Res Clin Pract; 2017; 11(5):501-521. PubMed ID: 28818558 [TBL] [Abstract][Full Text] [Related]
14. Fixed-dose combination of phentermine-topiramate for the treatment of obesity. Halpern B; Faria AM; Halpern A Expert Rev Clin Pharmacol; 2013 May; 6(3):235-41. PubMed ID: 23656337 [TBL] [Abstract][Full Text] [Related]
15. Review of pharmacotherapy options for the management of obesity. Bragg R; Crannage E J Am Assoc Nurse Pract; 2016 Feb; 28(2):107-15. PubMed ID: 26119641 [TBL] [Abstract][Full Text] [Related]
17. Pharmacological treatment of obesity in Europe: waiting for the arrival of the white blackbird. Rubio MA Endocrinol Nutr; 2014 Dec; 61(10):501-4. PubMed ID: 25434595 [No Abstract] [Full Text] [Related]
18. New obesity agents: lorcaserin and phentermine/topiramate. Fleming JW; McClendon KS; Riche DM Ann Pharmacother; 2013; 47(7-8):1007-16. PubMed ID: 23800750 [TBL] [Abstract][Full Text] [Related]